Spots Global Cancer Trial Database for Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Official Title: Microwave Ablation Combined With Simultaneous TACE Plus Sintilimab for Unresectable HCC.
Study ID: NCT04220944
Conditions
Study Description
Brief Summary: Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
Detailed Description: Hepatocellular carcinoma is the most frequent primary and ranked as the sixth most common neoplasm and the third leading cause of cancer death. Percutaneous ablation and TACE are the effective locoregional treatments for the patient with HCC. Moreover, some studies suggested that TACE combined with ablation could further improve the survival rate and reduce the post-operation complication. Although PD-1 inhibitor was approved by FDA for HCC, the latest RCT indicated that no significant difference was found in the ORR and PFS between the groups of PD-1 inhibitor and Sorafenib. Therefore, this study aims to assess the efficacy and safety of microwave ablation combined with simultaneous TACE plus PD-1 inhibitor for the non-resectable HCC.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai, Shanghai, China
Contact Details
Name: zhiping Yan, MD
Affiliation: Department of Interventional Radiology, Zhongshan Hospital, Fudan University
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
